Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Queensland Health
Federal Trade Commission
Deloitte
Cerilliant
UBS
Chinese Patent Office
Daiichi Sankyo
Express Scripts

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,005,260

« Back to Dashboard

Title:Tenascin-C nucleic acid ligands
Abstract: Methods are described for the identification and preparation of nucleic acid ligands to tenascin-C. Included in the invention are specific RNA ligands to tenascin-C identified by the SELEX method. Further included in the invention are methods for detecting the presence of a disease condition in a biological tissue in which tenascin-C is expressed.
Inventor(s): Hicke; Brian (Boulder, CO), Warren; Stephen (Fort Collins, CO), Parma; David (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:Jan 28, 2000
Application Number:10/031,193
Claims:1. A method for detecting the presence of a disease in a biological tissue which may contain said disease, wherein said disease is characterized by the expression of tenascin-C in said tissue and wherein said disease is selected from the group consisting of cancer, psoriasis, and atherosclerosis, the method comprising: a) attaching a marker that can be used in in vivo diagnostics to a tenascin-C nucleic acid ligand to form a marker-nucleic acid ligand complex wherein said tenascin-C nucleic acid ligand is selected from the group consisting of SEQ ID NO: 4 65; b) exposing said biological tissue which may contain said disease to said marker-nucleic acid ligand complex; and c) detecting the presence of said disease in said tissue by detecting the presence of said marker-nucleic acid ligand in said tissue.

2. The method of 1 wherein said marker is selected from from the group consisting of radionuclides, fluorophores, magnetic compounds, and biotin.

3. The method of 2 wherein said radionuclide is selected from the group consisting of technetium-99m (Tc-99m), Re-188, Cu-64, Cu-67, F-18, .sup.125I, .sup.131I, .sup.111In, .sup.32P, and .sup.186Re.

4. The method of 3 wherein said marker is technetium-99m.

5. The method of 4 wherein said tenascin-C nucleic acid ligand comprises a linker.

6. The method of 5 wherein said linker is (CH.sub.2CH.sub.2O).sub.6.

7. The method of 5, wherein said linker has the structure ##STR00001##

8. The method of 1 wherein said tenascin-C nucleic acid ligand is 5'-B-G667667CG-(CH.sub.2CH.sub.2O).sub.6-CGUCGCCGU77U667U6UUUU6CUCCCU65 wherein: all pyrimidines are 2'F; 6=2'OMe G; 7=2'OMe A; 5=3'--3'dT; and B=linker.

9. The method of 8 wherein said technetium-99m is associated with a chelator.

10. The method of 9, wherein said complex is ##STR00002##

11. The method of 10 wherein said complex is ##STR00003##

12. The method of 1 further comprising attaching a therapeutic or diagnostic agent to said complex.

13. The method of 1 wherein said disease is cancer.

14. The method of 1 wherein said tenascin-C nucleic acid ligand is identified by: i) contacting a candidate mixture of nucleic acids with tenascin-C wherein nucleic acids having an increased affinity to tenascin-C relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; ii) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; iii) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids with relatively higher affinity and specificity for binding to tenascin-C, whereby a nucleic acid ligand of tenascin-C is identified.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Julphar
Mallinckrodt
Medtronic
Colorcon
Chinese Patent Office
Harvard Business School
Farmers Insurance
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.